227 related articles for article (PubMed ID: 29265379)
1. Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.
Ray LA; Green R; Roche DJO; Bujarski S; Hartwell EE; Lim AC; Rohrbaugh T; Ghahremani D; Hutchison K; Miotto K
Alcohol Clin Exp Res; 2018 Mar; 42(3):613-623. PubMed ID: 29265379
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
Ray LA; Bujarski S; Chin PF; Miotto K
Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
[TBL] [Abstract][Full Text] [Related]
3. Alcohol Cue-Induced Ventral Striatum Activity Predicts Subsequent Alcohol Self-Administration.
Lim AC; Green R; Grodin EN; Venegas A; Meredith LR; Donato S; Burnette E; Ray LA
Alcohol Clin Exp Res; 2020 Jun; 44(6):1224-1233. PubMed ID: 32406553
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
5. The Interplay Between Subjective Response to Alcohol, Craving, and Alcohol Self-Administration in the Human Laboratory.
Green R; Grodin E; Lim AC; Venegas A; Bujarski S; Krull J; Ray LA
Alcohol Clin Exp Res; 2019 May; 43(5):907-915. PubMed ID: 30860603
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
8. Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.
Ray LA; Hutchison KE; Ashenhurst JR; Morrow AL
Alcohol Clin Exp Res; 2010 Aug; 34(8):1479-87. PubMed ID: 20528823
[TBL] [Abstract][Full Text] [Related]
9. Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent.
Lim AC; Ghahremani DG; Grodin EN; Green R; Bujarski S; Hartwell EE; Courtney KE; Hutchison K; Miotto K; Ray LA
Drug Alcohol Depend; 2019 Jul; 200():181-190. PubMed ID: 31160146
[TBL] [Abstract][Full Text] [Related]
10. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
[TBL] [Abstract][Full Text] [Related]
11. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
12. Associations of OPRM1 A118G and alcohol sensitivity with intravenous alcohol self-administration in young adults.
Hendershot CS; Claus ED; Ramchandani VA
Addict Biol; 2016 Jan; 21(1):125-35. PubMed ID: 25039301
[TBL] [Abstract][Full Text] [Related]
13. Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol.
Ashenhurst JR; Bujarski S; Ray LA
Pharmacol Biochem Behav; 2012 Dec; 103(2):253-9. PubMed ID: 22954510
[TBL] [Abstract][Full Text] [Related]
14. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Kranzler HR; Armeli S; Covault J; Tennen H
Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers.
Green R; Bujarski S; Lim AC; Venegas A; Ray LA
Exp Clin Psychopharmacol; 2019 Jun; 27(3):257-264. PubMed ID: 30628813
[TBL] [Abstract][Full Text] [Related]
16. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
[TBL] [Abstract][Full Text] [Related]
17. Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation.
Hernandez-Avila CA; Covault J; Wand G; Zhang H; Gelernter J; Kranzler HR
Pharmacogenet Genomics; 2007 Dec; 17(12):1031-8. PubMed ID: 18004207
[TBL] [Abstract][Full Text] [Related]
18. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis.
Ray LA; Green R; Roche DJO; Magill M; Bujarski S
Addict Biol; 2019 Nov; 24(6):1138-1152. PubMed ID: 31148304
[TBL] [Abstract][Full Text] [Related]
20. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
Kim SG; Kim CM; Choi SW; Jae YM; Lee HG; Son BK; Kim JG; Choi YS; Kim HO; Kim SY; Oslin DW
Psychopharmacology (Berl); 2009 Jan; 201(4):611-8. PubMed ID: 18795264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
